Weekly Recap | ARKG.US +13.35%, AI healthcare leads genomics themeWeekly Review·Sep 19 at 07:15 AMARKG+2.12%
Weekly Recap | Twist Bioscience +31.26%, signs deal with Lilly TuneLabWeekly Review·Sep 19 at 06:54 AMTWST+1.31%
The Nasdaq Biotechnology Index rose over 1.6%, outperforming the three major U.S. stock indices. Cabaletta Bio increased by 26.28%, Altimmune, Prime Medicine, Personalis, and Corvus Pharmaceuticals rose by 16.67%-15.21%, and GRAIL increased by 15.03%. Aardvark Therapeutics fell by 4.68%, Monte Rosa Therapeutics dropped by 4.99%, Bioage Labs decreased by 6.06%, and Legend Bio declined by 6.84%Wallstreetcn·Jan 22 at 11:21 PMPRME+6.43%BIB+3.09%
The Nasdaq Biotechnology Index closed up 1.85%, outperforming both small-cap indices and the three major U.S. stock indicesWallstreetcn·Jul 16, 2025 at 08:42 PMPRME+6.43%SMMT+0.80%
The Nasdaq Biotechnology Index rose by 1.11%. Among the constituent stocks, Prime Medicine increased by 10.46%, while Amylyx Pharmaceuticals, Lexicon Pharma, Kyverna Therapeutics, and Foghorn rose by 9.51% to 8.89%. In contrast, Amarin fell by 5.08%, Alpha Teknova dropped by 6.65%, and Q32 Bio saw a significant decline of 23.68%Wallstreetcn·Jul 14, 2025 at 09:12 PMLXRX+3.92%AMLX+1.11%
Prime Medicine Inc. (PRME) maintained an increase of over 32.4%, once achieving the best intraday performance since September 2024, with a cumulative increase of approximately 67.3% over the last five trading days, attracting investor interest with its gene editing technologyWallstreetcn·Jul 7, 2025 at 04:10 PMPRME+6.43%
The Nasdaq Biotechnology Index rose by 1.3%, temporarily outperforming the three major U.S. stock indicesWallstreetcn·Jul 2, 2025 at 02:11 PMPGEN+2.66%PRME+6.43%
